A comparison of therapeutic trends in myocardial infarction.
Milasinovic
D
D
Department of Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria.
Teischinger
L
L
Luerzer
G
G
Mohl
W
W
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D017225:Atherectomy, Coronary / Q000379:methods; D003131:Combined Modality Therapy; D054855:Drug-Eluting Stents; D017052:Hospital Mortality; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage; D000451:Mineralocorticoid Receptor Antagonists; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy*; D009204:Myocardial Revascularization / Q000379:methods*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D015912:Thrombolytic Therapy / Q000379:methods*
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D000451:Mineralocorticoid Receptor Antagonists; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab